Catalyst Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
5299004O0R5XXLA5H544 - ISIN
US14888U1016 (CPRX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€31.84 79.1% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Read full profile
Fundamentals
- Net revenue
€476.37M - Gross margin
82.4% - EBIT
€207.62M - EBIT margin
43.6% - Net income
€177.98M - Net margin
37.4%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Elsbernd Brian | Chief Compliance/Legal Officer |
|
|
|
|
| Tierney David S | N/A |
|
|
|
|
| Daly Richard J | President and CEO |
|
|
|
|
| Miller Steve | Chief Op. & Scientific Officer |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)